Hiroshi Fukuhara

Summary

Country: Japan

Publications

  1. ncbi Oncolytic virus therapy for prostate cancer
    Hiroshi Fukuhara
    Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Int J Urol 17:20-30. 2010
  2. ncbi Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?
    Haruki Kume
    Department of Urology, University of Tokyo Hospital, Tokyo, Japan
    J Urol 185:1611-4. 2011
  3. ncbi Docetaxel as a vital option for corticosteroid-refractory prostate cancer
    Haruki Kume
    Department of Urology, The University of Tokyo Hospital, Hongo 7 3 1, Bunkyo ku, Tokyo 113 8655, Japan
    Int Urol Nephrol 43:1081-7. 2011
  4. ncbi Core lower urinary tract symptom score (CLSS) for the assessment of female lower urinary tract symptoms: a comparative study
    Tetsuya Fujimura
    Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Int J Urol 18:778-84. 2011
  5. ncbi Association of rs6983561 polymorphism at 8q24 with prostate cancer mortality in a Japanese population
    Motofumi Suzuki
    Department of Urology, Graduate School of Medicine, The University of Tokyo, Japan
    Clin Genitourin Cancer 9:46-52. 2011
  6. ncbi Oncolytic herpes simplex virus type 1 and host immune responses
    Hiroshi Fukuhara
    Department of Urology, The University of Tokyo, Bunkyo ku, Tokyo, Japan
    Curr Cancer Drug Targets 7:149-55. 2007
  7. ncbi Distant metastasis of renal cell carcinoma with a diameter of 3 cm or less-which is aggressive cancer?
    Haruki Kume
    Department of Urology, Tokyo University Hospital, Tokyo, Japan
    J Urol 184:64-8. 2010

Collaborators

Detail Information

Publications7

  1. ncbi Oncolytic virus therapy for prostate cancer
    Hiroshi Fukuhara
    Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Int J Urol 17:20-30. 2010
    ..The result shows the oncolytic virus therapy is promising toward clinical application. Here, we review the recent advances in the field and summarize the results from clinical trials...
  2. ncbi Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?
    Haruki Kume
    Department of Urology, University of Tokyo Hospital, Tokyo, Japan
    J Urol 185:1611-4. 2011
    ..Renal cell carcinoma is sometimes associated with bone metastasis. Several risk factors have been reported but some are still controversial. Also, the significance of laboratory tests has not been fully examined for such cases...
  3. ncbi Docetaxel as a vital option for corticosteroid-refractory prostate cancer
    Haruki Kume
    Department of Urology, The University of Tokyo Hospital, Hongo 7 3 1, Bunkyo ku, Tokyo 113 8655, Japan
    Int Urol Nephrol 43:1081-7. 2011
    ..The efficacy of docetaxel (TAX) chemotherapy for corticosteroid-refractory refractory prostate cancer (CRPC) is uncertain...
  4. ncbi Core lower urinary tract symptom score (CLSS) for the assessment of female lower urinary tract symptoms: a comparative study
    Tetsuya Fujimura
    Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Int J Urol 18:778-84. 2011
    ..The aim of the present study was to evaluate the performance of the CLSS in women compared with the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS)...
  5. ncbi Association of rs6983561 polymorphism at 8q24 with prostate cancer mortality in a Japanese population
    Motofumi Suzuki
    Department of Urology, Graduate School of Medicine, The University of Tokyo, Japan
    Clin Genitourin Cancer 9:46-52. 2011
    ..We genotyped 518 Japanese patients with prostate cancer and analysed their survival retrospectively. As a result, patients with the CA/CC genotype of rs6983561 survived significantly longer than those with the AA genotype (P = .033)...
  6. ncbi Oncolytic herpes simplex virus type 1 and host immune responses
    Hiroshi Fukuhara
    Department of Urology, The University of Tokyo, Bunkyo ku, Tokyo, Japan
    Curr Cancer Drug Targets 7:149-55. 2007
    ..Elucidation of the role of the host immune system in oncolytic HSV-1 therapy is the key to establishing the approach as a useful clinical means for cancer treatment...
  7. ncbi Distant metastasis of renal cell carcinoma with a diameter of 3 cm or less-which is aggressive cancer?
    Haruki Kume
    Department of Urology, Tokyo University Hospital, Tokyo, Japan
    J Urol 184:64-8. 2010
    ..However, metastasis develops in a small number of cases, which cannot be ignored. We investigated the clinicopathological characters of small renal cell carcinoma with metastasis to further understand this condition...